Trial · NCT07543458
Therapeutics for Moderate and Severe Dengue
NCT07543458, Phase 3, Not yet recruiting, Oxford University Clinical Research Unit, Vietnam
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Therapeutics for Moderate and Severe Dengue. Trials, record NCT07543458. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07543458
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Therapeutics for Moderate and Severe Dengue
- NCT number
- NCT07543458
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 8,800 participants, estimated
- Lead sponsor
- Oxford University Clinical Research Unit, Vietnam
- Conditions
- Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections, Hemorrhagic Fever
- Interventions
- Placebo, Dexamethasone, N-Acetylcysteine, Standard of care, Baricitinib
- First posted
- 2026-04-21
- Last updated
- 2026-04-21
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression to severe dengue/critical dengue | between randomization to hospital discharge (average of 5 days) | In the trial, baseline severity of dengue will be assessed at the start of study participation. Participants will be defined in accordance with our case definitions as having moderate, severe or critical dengue, based on clinical signs and symptoms, laboratory parameters, and if they have evidence of organ failure with or without need for organ support. At hospital discharge or following death, we will capture if the participant had evidence of at least one of: * Progression to Severe dengue, in a participant with moderate dengue at enrolment, * Progression to Critical dengue, in a participant with moderate or severe dengue at enrolment. |
| Primary | All-cause mortality within 30 days | Day 30 | All-cause mortality in any participant. Assessed as dead or alive |
| Secondary | Length of hospital stay | At hospital discharge (average of 5 days) | Number of days from hospital admission to discharge |
| Secondary | Lowest recorded platelet count | Between randomisation and hospital discharge (average of 5 days) | Lowest recorded platelet count between randomisation and hospital discharge |
| Secondary | Acute kidney injury | Between randomisation and hospital discharge (average of 5 days) | Serum creatinine \> 3.5 mg/dL or more than double baseline |
| Secondary | Liver involvement | Between randomisation and hospital discharge (average of 5 days) | Highest recorded ALT or AST |
| Secondary | Change in ALT/AST | at randomisation, day 2 (if feasible) and day 4 or hospital discharge (average on day 5) if sooner | N-acetylcysteine treatment comparison only. Fold change in ALT or AST |
| Secondary | Highest bilirubin | Between randomisation and hospital discharge (average of 5 days) | N-acetylcysteine treatment comparison only. Highest recorded bilirubin |
| Secondary | Highest INR | Between randomisation and hospital discharge (average of 5 days) | N-acetylcysteine treatment comparison only. Highest recorded INR |
| Secondary | Safety reporting: Suspected Severe Adverse Reactions | During hospital stay (average of 5 days) and at day 30 follow up | Suspected serious adverse reactions (SSARs) excluding primary outcomes |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07543458
GET https://conductscience.org/api/trials/v1/NCT07543458/registered